NCOA3 and urinary bladder cancer: Though NCOA3 mutations were a favorable prognostic factor in the combined cohort (Fig. 6A), NCOA3 mutations were predominant in colorectal cancer patients, followed by melanoma and bladder cancer patients (Fig. 6B).